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December 20101728 AbstractsPatients with SVT that do not have VTE at presentation can develop this
complication in the following 3 months.
Summary: SVT is painful, relatively common, and is thought to have a
benign prognosis. However, there is accumulating evidence that SVT often
occurs with DVT or pulmonary embolism (PE). DVT appears to be present
in about 6% to 53% of patients with SVT and PE in between 0% and 10% of
patients with SVT (Leon L et al, Eur J Vasc Endovasc Surg 2005;29:10-7).
The authors performed this large observational study to determine the
prevalence of concurrent SVT and VTE, to assess how SVT is treated, and to
determine the 3-month incidence of thromboembolic complications in
patients with SVT. Risk factors for VTE complications in patients presenting
with SVT were also determined. This was a national cross-sectional and
prospective epidemiologic cohort study performed in France. Office- and
hospital-based vascular medical specialists registered with the Societe Fran-
ciase de Medecine Vasculaire or Societe Franciase de Phlebologie were
invited to enroll patients in the study. To be eligible for the study, patients
had to be aged18 years with symptomatic lower extremity SVT. SVT was
defined as subcutaneous noncompressible hypoechoic area in the course of
an identifiable superficial vein 5 cm in length. Excluded patients were
those who had undergone surgery 10 days, those where SVT occurred
30 days after sclerotherapy, and those in whom follow-up was not consid-
ered feasible. The study included 844 consecutive patients (547 women)
with symptomatic lower extremity SVT. Median age was 65 years. At
presentation 210 patients (24.9%) also had DVT or symptomatic PE. Of the
600 patients without DVT or PE at study inclusion, and who were eligible
for 3-month follow-up, VTE complications developed in 58 (10.2%) at 3
months (PE, 0.5%; DVT, 2.8%; extension of SVT, 3.3%; recurrence of SVT,
1.9%). A total of 540 patients (90.5%) received anticoagulants. Risk factors
for complications at 3 months were history of DVT or PE, previous cancer,
absence of varicose veins, and male sex.
Comment: The study indicates symptomatic SVT is not necessarily
benign. About 25% of the patients will have symptomatic PE or DVT at
presentation, and in an additional 10%, some manifestation of VTE or
complication of their SVT will develop at 3 months. Given the percentage of
patients who present for evaluation of symptoms consistent with SVT and
who also have DVT, it would appear prudent to perform a venous ultra-
sound examination in all patients with suspected SVT. This would appear
especially so if anticoagulation is going to be withheld. Patients with
identifiable risk factors for development of VTE after SVT and who are not
going to be treated with anticoagulation should be considered for follow-up
duplex ultrasound imaging.
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Conclusion: Patients with inferior vena cava (IVC) filters that are
inserted after venous thromboembolism (VTE) who are managed with
continued therapeutic anticoagulation have a favorable prognosis whenmanaged with a protocol that includes clinical surveillance, ultrasound
examination of the IVC filter, and greater degrees of anticoagulation if a
filter clot is detected.
Summary: The authors hypothesized that in patients with IVC filters,
anticoagulation indefinitely would be effective in preventing filter occlusion
and venous thrombotic complications. They prospectively evaluated the
effect of long-term anticoagulation on the frequency of symptomatic venous
thromboembolism (VTE) and IVC patency and flow impairment in a cohort
of patients with IVC filters. The patients were monitored for clinical recur-
rence of VTE as well as with serial ultrasound examinations of the IVC filter.
They divided the ultrasound examinations into three categories: (1) those
that showed no evidence of filter thrombus, (2) those that showed slight
inclusion of filter thrombus, with slight inclusion defined as when color
Doppler indicated more than half but less than all of the IVC filter to be
occluded by thrombus, and (3) large, but incomplete occlusion, was defined
when phasic flow modulated by breathing maneuvers was reduced to be-
tween 10% and 50% of the IVC filter field. Patients with slight occlusion had
frequency of clinic visits and international normalized ratio (INR) determi-
nations increased to approximately weekly, with the target INR of 2.5
unchanged. In patients with larger and complete occlusion, their anticoag-
ulation therapy was switched to low-molecular-weight heparin at therapeu-
tic doses for 5 to 7 days, and then to about 75% of the therapeutic dosage
after 1 week. They weremonitored by ultrasound imaging every 1 to 2 weeks
until the occlusion normalized by ultrasound criteria. At that point they were
then transitioned back to oral anticoagulation therapy. The authors also
followed a cohort of patients with persistent anticoagulation who did not
have IVC filters.
There were 121 patients in the IVC filter cohort under observation.
Symptomatic DVT occurred in 24 (20%; 95% CI, 14%-28%). Symptomatic
pulmonary embolism (one fatal) was diagnosed in six patients (5%; 95% CI,
2%-10%). There were 45 episodes of filter clot in 36 patients (30%; 95% CI,
22%-38%). There were 30 episodes of slight occlusion, 13 episodes of large
occlusion, and 2 episodes of complete filter occlusion. With the manage-
ment protocol detailed above, all episodes of slight occlusion resolved. The
average period of low-molecular-weight heparin treatment in the 15 epi-
sodes of large or complete occlusion was 4 to 6 weeks. All instances of large
or complete occlusion resolved with the management protocol above. The
longest duration until ultrasound resolution of IVC filter complete occlu-
sion was 8 weeks. The rate ofmajor bleeding in the filter cohort was 6.6% and
was similar to the 5.8% in patients with persistent anticoagulation without
IVC filters.
Comment: The authors are proposing an ultrasound-based follow-up
protocol for patients with permanently implanted IVC filters who can be
anticoagulated. The data would be more convincing if independent observ-
ers had confirmed the IVC filter ultrasound examinations. Nevertheless, the
idea of serially monitoring IVC filters and increasing the intensity of antico-
agulation or increasing the intensity of monitoring of anticoagulation in
response to ultrasound-detected filter clot is interesting. Who will provide
such monitoring is a question, but logically, those who perform procedures
on patients should be vested in the long-term outcome and monitoring of
those procedures.
